论文部分内容阅读
采用比浊法观察到ＡＰＩ０１３４显著抑制二磷酸腺苷（ＡＤＰ）、肾上腺素（Ａｄｒ）、花生四烯酸（ＡＡ）和胶原（Ｃｏｌｌ）诱导的人和大鼠血小板聚集。ＡＰＩ０１３４体外给药（２８．８～９１０ｍｇ·Ｌ－１）呈剂量依赖性的明显抑制ＡＤＰ、Ａｄｒ和ＡＡ诱导的人血小板聚集，其中对ＡＤＰ诱导的血小板聚集抑制作用最强，１ｍｉｎ和５ｍｉｎ时的半抑制浓度（ＩＣ５０）分别为１３４ｍｇ·Ｌ－１和７６．６ｍｇ·Ｌ－１，对Ａｄｒ诱导的血小板聚集之ＩＣ５０分别为１９４和１３７．６ｍｇ·Ｌ－１，对ＡＡ诱导的血小板聚集抑制作用较弱，５ｍｉｎ时的ＩＣ５０为２０３ｍｇ·Ｌ－１，ｉｖＡＰＩ０１３４７０和１００ｍｇ·ｋｇ－１，对ＡＤＰ和Ｃｏｌｌ诱导的大鼠血小板聚集也呈显著抑制作用，抑制率分别为２７．８％～３９．５％和２４．３％～３５．０％。
API0134 was found to significantly inhibit platelet aggregation in human and rat induced by adenosine diphosphate (ADP), adrenaline (Adr), arachidonic acid (AA) and collagen (Coll) by turbidimetry. Administration of API0134 in vitro (28.8-910 mg · L-1) significantly inhibited platelet aggregation induced by ADP, Adr and AA in a dose-dependent manner, with the strongest inhibitory effect on ADP-induced platelet aggregation, at 1 and 5 min The IC50 values were 134 mg · L-1 and 76.6 mg · L-1, respectively, and the IC50 of Adr-induced platelet aggregation were 194 and 137.6 mg · L-1, respectively. The inhibitory effect on AA-induced platelet aggregation Weak, IC50 at 5min of 203mg · L-1, ivAPI013470 and 100mg · kg-1, ADP and Coll induced rat platelet aggregation was also significantly inhibited, the inhibition rates were 27.8% ~ 39.5 % And 24.3% ~ 35.0%.